Unicycive Therapeutics (UNCY) Total Current Liabilities (2020 - 2026)
Unicycive Therapeutics' (UNCY) quarterly Total Current Liabilities came in at $26.5 million in Q1 2026, up 58.82% YoY from $16.7 million in Q1 2025, and up 39.85% on a QoQ basis from $18.9 million in Q4 2025.
Unicycive Therapeutics (UNCY) Total Current Liabilities (2020 - 2026) Analysis & Trends
Unicycive Therapeutics (UNCY) has 7 years of Total Current Liabilities data on file, last reported at $26.5 million in Q1 2026.
- Quarterly Total Current Liabilities rose 58.82% year-over-year to $26.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $26.5 million (up 58.82% YoY) and the FY2025 annual result came in at $18.9 million, down 21.48% from the prior year.
- Total Current Liabilities climbed to $26.5 million in Q1 2026, from $18.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $30.3 million in Q1 2024 to a low of $2.4 million in Q1 2022.
- A 5-year average of $14.4 million and a median of $15.4 million in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities soared 603.44% — and 2025, when it slumped 44.93%.
- Tracing UNCY's Total Current Liabilities over 5 years: stood at $3.3 million in 2022, then jumped by 433.92% to $17.5 million in 2023, then jumped by 37.56% to $24.1 million in 2024, then declined by 21.48% to $18.9 million in 2025, then surged by 39.85% to $26.5 million in 2026.
- The last three Total Current Liabilities figures came in at $26.5 million (Q1 2026), $18.9 million (Q4 2025), and $13.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.51 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 2.49 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 438.74 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 630.93 Mn |
| 10 | Unicycive Therapeutics | 151.01 Mn | 151.01 Mn | - | 18.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.70 Mn |
| Mar 31, 2026 | 26.49 Mn |
| Dec 31, 2025 | 18.94 Mn |
| Sep 30, 2025 | 13.13 Mn |
| Jun 30, 2025 | 13.57 Mn |
| Mar 31, 2025 | 16.68 Mn |
| Dec 31, 2024 | 24.12 Mn |
| Sep 30, 2024 | 10.46 Mn |
| Jun 30, 2024 | 13.09 Mn |
| Mar 31, 2024 | 30.28 Mn |
| Dec 31, 2023 | 17.53 Mn |
| Sep 30, 2023 | 15.46 Mn |
| Jun 30, 2023 | 15.42 Mn |
| Mar 31, 2023 | 15.97 Mn |
| Dec 31, 2022 | 3.28 Mn |
| Sep 30, 2022 | 5.52 Mn |
| Jun 30, 2022 | 2.83 Mn |
| Mar 31, 2022 | 2.40 Mn |
| Dec 31, 2021 | 2.11 Mn |
| Sep 30, 2021 | 785,000.00 |